A new breast cancer pill that can slow the progression of advanced disease has been approved for use on the NHS in England and Wales, offering new hope to thousands of women. The twice-daily tablet, capivasertib (also marketed as Truqap), targets the most common form of advanced breast cancer and could benefit around 3,000 women each year. The approval follows clinical trials showing it significantly delays disease progression when compared to existing treatments alone. How the drug works Unlike many existing treatments, capivasertib works by blocking a protein called AKT that drives cancer cell growth. This targeted approach helps slow … Continue reading NHS Approves New Breast Cancer Pill That Doubles Time Before Progression